145742-38-7Relevant articles and documents
An SNAr approach to sterically hindered ortho -alkoxybenzaldehydes for the synthesis of olefin metathesis catalysts
Engle, Keary M.,Luo, Shao-Xiong,Grubbs, Robert H.
, p. 4213 - 4220 (2015)
A three-step procedure has been developed for preparing ortho-alkoxybenzaldehydes from ortho-fluorobenzaldehydes that tolerates the use of sterically hindered sodium alkoxide nucleophiles. The protocol is modular and operationally convenient. The ortho-alkoxybenzaldehyde products can be converted in one additional step to ortho-alkoxystyrenes by a Wittig reaction. These styrenes are precursors to the chelating benzylidene moiety in a proposed series of novel ruthenium complexes for use in olefin metathesis. Chelation with three representative styrenes has been demonstrated.
LATE SV40 (LSF) INHIBITORS
-
Paragraph 0407; 0456-0458, (2020/02/20)
The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubu
C-H bond functionalization via hydride transfer: synthesis of dihydrobenzopyrans from ortho-vinylaryl akyl ethers
McQuaid, Kevin M.,Long, Jonathan Z.,Sames, Dalibor
supporting information; experimental part, p. 2972 - 2975 (2009/12/05)
The hydride transfer initiated cyclization ("HT-cyclization") of aryl alkyl ethers, which leads to direct coupling of sp3 C-H bonds and activated alkenes, is reported. Readily available salicylaldehyde derived ethers are converted in one step to dihydrobenzopyrans, an important class of heteroarenes frequently found in biologically active compounds. This process has not been previously reported, in contrast to known HTcyclizations of the corresponding fert-amines ("tert-amino effect" reactions).
RECEPTOR FUNCTION REGULATING AGENT
-
Page/Page column 86-87, (2010/11/23)
An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.